Literature DB >> 10206309

Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment.

F de Vathaire1, M Hawkins, S Campbell, O Oberlin, M A Raquin, J Y Schlienger, A Shamsaldin, I Diallo, J Bell, E Grimaud, C Hardiman, J L Lagrange, N Daly-Schveitzer, X Panis, J M Zucker, H Sancho-Garnier, F Eschwège, J Chavaudra, J Lemerle.   

Abstract

The variation in the risk of solid second malignant neoplasms (SMN) with time since first cancer during childhood has been previously reported. However, no study has been performed that controls for the distribution of radiation dose and the aggressiveness of past chemotherapy, which could be responsible for the observed temporal variation of the risk. The purpose of this study was to investigate the influence of the treatment on the long-term pattern of the incidence of solid SMN after a first cancer in childhood. We studied a cohort of 4400 patients from eight centres in France and the UK. Patients had to be alive 3 years or more after a first cancer treated before the age of 17 years and before the end of 1985. For each patient in the cohort, the complete clinical, chemotherapy and radiotherapy history was recorded. For each patient who had received external radiotherapy, the dose of radiation received by 151 sites of the body were estimated. After a mean follow-up of 15 years, 113 children developed a solid SMN, compared to 12.3 expected from general population rates. A similar distribution pattern was observed among the 1045 patients treated with radiotherapy alone and the 2064 patients treated with radiotherapy plus chemotherapy; the relative risk, but not the excess absolute risk, of solid SMN decreased with time after first treatment; the excess absolute risk increased during a period of at least 30 years after the first cancer. This pattern remained after controlling for chemotherapy and for the average dose of radiation to the major sites of SMN. It also remained when excluding patients with a first cancer type or an associated syndrome known to predispose to SMN. When compared with radiotherapy alone, the addition of chemotherapy increases the risk of solid SMN after a first cancer in childhood, but does not significantly modify the variation of this risk during the time after the first cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206309      PMCID: PMC2362818          DOI: 10.1038/sj.bjc.6690300

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Time variations in the risk of cancer following irradiation in childhood.

Authors:  M P Little; M M Hawkins; R E Shore; M W Charles; N G Hildreth
Journal:  Radiat Res       Date:  1991-06       Impact factor: 2.841

2.  Risk of leukemia after chemotherapy and radiation treatment for breast cancer.

Authors:  R E Curtis; J D Boice; M Stovall; L Bernstein; R S Greenberg; J T Flannery; A G Schwartz; P Weyer; W C Moloney; R N Hoover
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

3.  Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapy.

Authors:  I Diallo; A Lamon; A Shamsaldin; E Grimaud; F de Vathaire; J Chavaudra
Journal:  Radiother Oncol       Date:  1996-03       Impact factor: 6.280

Review 4.  Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.

Authors:  J M Andrieu; N Ifrah; C Payen; J Fermanian; Y Coscas; G Flandrin
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

5.  Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Authors:  M M Hawkins; L M Wilson; M A Stovall; H B Marsden; M H Potok; J E Kingston; J M Chessells
Journal:  BMJ       Date:  1992-04-11

6.  Calculation of the dose delivered to organs outside the radiation beams.

Authors:  P Francois; C Beurtheret; A Dutreix
Journal:  Med Phys       Date:  1988 Nov-Dec       Impact factor: 4.071

7.  Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group.

Authors:  M A Tucker; P H Jones; J D Boice; L L Robison; B J Stone; M Stovall; R D Jenkin; J H Lubin; E S Baum; S E Siegel
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

8.  Leukemia after therapy with alkylating agents for childhood cancer.

Authors:  M A Tucker; A T Meadows; J D Boice; M Stovall; O Oberlin; B J Stone; J Birch; P A Voûte; R N Hoover; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

9.  A mathematical child phantom for the calculation of dose to the organs at risk.

Authors:  P Francois; C Beurtheret; A Dutreix; F De Vathaire
Journal:  Med Phys       Date:  1988 May-Jun       Impact factor: 4.071

10.  Incidence of second primary tumours among childhood cancer survivors.

Authors:  M M Hawkins; G J Draper; J E Kingston
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  20 in total

1.  Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study.

Authors:  Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

Review 2.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

3.  Local radiation dose and solid second malignant neoplasms after childhood cancer in Germany: a nested case-control study.

Authors:  Ulrike Hennewig; Peter Kaatsch; Maria Blettner; Claudia Spix
Journal:  Radiat Environ Biophys       Date:  2014-05-27       Impact factor: 1.925

Review 4.  Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects.

Authors:  Saro H Armenian; Leslie L Robison
Journal:  Curr Opin Pediatr       Date:  2013-02       Impact factor: 2.856

5.  DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements.

Authors:  Christine E Lehman; Laura W Dillon; Yuri E Nikiforov; Yuh-Hwa Wang
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

6.  Secondary cancers after a childhood cancer diagnosis: a nationwide hospital-based retrospective cohort study in Japan.

Authors:  Yasushi Ishida; Dongmei Qiu; Miho Maeda; Junichiro Fujimoto; Hisato Kigasawa; Ryoji Kobayashi; Maho Sato; Jun Okamura; Shinji Yoshinaga; Takeshi Rikiishi; Hiroyuki Shichino; Chikako Kiyotani; Kazuko Kudo; Keiko Asami; Hiroki Hori; Hiroshi Kawaguchi; Hiroko Inada; Souichi Adachi; Atsushi Manabe; Tatsuo Kuroda
Journal:  Int J Clin Oncol       Date:  2015-11-30       Impact factor: 3.402

Review 7.  Surviving childhood cancer: the impact on life.

Authors:  Robert E Goldsby; Denah R Taggart; Arthur R Ablin
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 8.  High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance.

Authors:  Melissa M Hudson; Daniel A Mulrooney; Daniel C Bowers; Charles A Sklar; Daniel M Green; Sarah S Donaldson; Kevin C Oeffinger; Joseph P Neglia; Anna T Meadows; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

Review 9.  A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction.

Authors:  X George Xu; Bryan Bednarz; Harald Paganetti
Journal:  Phys Med Biol       Date:  2008-06-09       Impact factor: 3.609

Review 10.  Paediatric medicines research in the UK: how to move forward?

Authors:  Ian Wong; Dimah Sweis; Judith Cope; Alexander Florence
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.